Publication
Comorbidity burden and effectiveness of immunotherapy in metastatic renal cell carcinoma
Multi-institutional study evaluating the impact of comorbidity burden on treatment outcomes and adverse events in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor–based combinations.
Citation
Yekeduz E, Zarba M, Saad E, El Hajj Chehade R, Eid M, Saliby RM, Steiner C, Machaalani M, Nawfal R, Semaan K, Ürün Y, Heng DYC, Choueiri TK. Comorbidity burden and effectiveness of immunotherapy in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2025;23(4):102385. doi:10.1016/j.clgc.2025.102385.